CoChat

Systematic review and meta-analysis of randomized controlled trials of ketamine in the treatment of refractory anxiety spectrum disorders

Open access
Whittaker, Elizabeth, Dadabayev, Alisher R., Joshi, Sonalee A., Glue, Paul · 2021 · Therapeutic Advances in Psychopharmacology

The DOI matches its Crossref record; 42 of the 42 references it cites were found in a registry or an index.

Abstract

Background: Anxiety disorders are common, associated with significant burden of disease, and have high levels of treatment resistance. Low-dose ketamine has been extensively studied in treatment-resistant depression, with fewer reports in treatment-resistant anxiety disorders. Aims: This systematic review and meta-analysis collected efficacy, safety, and tolerability data for ketamine as a treatment for anxiety spectrum disorders. Methods: We conducted a systematic search for randomized controlled trials (RCTs) of acute ketamine treatment for patients with anxiety disorders. Open-label trials of ketamine maintenance therapy were also considered. Qualitative and, where possible, quantitative syntheses of findings were performed using Review Manager software (RevMan). Acute dose-response and maintenance treatment data were also collected. Results: There were six eligible acute RCTs – two in social anxiety disorder (SAD), three in post-traumatic stress disorder (PTSD), and one in obsessive-compulsive disorder (OCD). Four of the six showed significant improvement in anxiety rating scores in ketamine compared with control groups. Pooled analysis showed ketamine was associated with an increased likelihood of treatment response for SAD (odds ratio (OR): 28.94; 95% confidence interval [CI]: 3.45–242.57; p = 0.002) but not for PTSD (OR: 2.03; 95% CI: 0.67–6.15; p = 0.21). A dose-response profile was observed for ketamine and changes in SAD symptoms, with doses ⩾0.5 mg/kg associated with greater reduction in anxiety rating scores than lower doses. Ketamine maintenance therapy was associated with sustained anxiolytic effects and improved social and/or work functioning. Conclusion: These preliminary analyses suggest that acute ketamine may be broadly effective across treatment-resistant anxiety spectrum disorders. These effects can be prolonged with maintenance treatment. Future studies will be needed to provide critical knowledge gaps around off-label use, side effects, and potential risks for abuse in clinical settings.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1177/20451253211056743

Cites

42 of 42 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1. PRISMA flow diagram.
Figure 1. PRISMA flow diagram.CC BY-NC · PubMed Central
Figure 2. Risk of bias in included acute treatment RCTs (n = 6).
Figure 2. Risk of bias in included acute treatment RCTs (n = 6).CC BY-NC · PubMed Central
Figure 3. Responder analysis for patients with SAD and PTSD.
Figure 3. Responder analysis for patients with SAD and PTSD.CC BY-NC · PubMed Central
Figure 4. Effects of ketamine (solid lines) and control (dashed lines) on mean Clinician-Administered Dissociative States Scale (CADSS) scores over time.
Figure 4. Effects of ketamine (solid lines) and control (dashed lines) on mean Clinician-Administered Dissociative States Scale (CADSS) scores over time.CC BY-NC · PubMed Central
Figure 5. Side effects (ketamine compared to controls).
Figure 5. Side effects (ketamine compared to controls).CC BY-NC · PubMed Central
Figure 6. Relationship between acute ketamine dose and change in anxiety rating scores at 24 hours post-dose.
Figure 6. Relationship between acute ketamine dose and change in anxiety rating scores at 24 hours post-dose.CC BY-NC · PubMed Central
Figure 7. Change in anxiety rating score over time during ketamine maintenance therapy.
Figure 7. Change in anxiety rating score over time during ketamine maintenance therapy.CC BY-NC · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 42 references

Research works printed but not linked: 2

  1. Review Manager (RevMan) , version 5.3. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2014.
  2. Spielberger CD, 1983, Manual for the State-Trait Anxiety Inventory (Form Y)

Cited by

See all 67

Metadata

Authors
Whittaker, E., Dadabayev, A. R., Joshi, S. A., & Glue, P.
Affiliations
  • University of Otago (NZ)
  • Ralph H. Johnson VA Medical Center (US)
  • University of Michigan (US)
Corresponding author
Glue, Paul
Venue
Therapeutic Advances in Psychopharmacology
Published
2021-01
Volume
11
Pages
20451253211056743-20451253211056743
ISSN
  • 2045-1253 (ISSN-L)
  • 2045-1261
OpenAlex
W4200066931
Cited by
56
References
42
Citations by year
2026: 9 · 2025: 13 · 2024: 10 · 2023: 14 · 2022: 10
FWCI
1.08
Type
journal article
Language
en
Open access
Locations
  • Therapeutic Advances in Psychopharmacology (publishedVersion, cc-by-nc)
  • PubMed Central (publishedVersion, cc-by-nc)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Topics
  • Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
  • Health Sciences › Medicine › Psychiatry and Mental health › Electroconvulsive Therapy Studies
  • Social Sciences › Psychology › Experimental and Cognitive Psychology › Anxiety, Depression, Psychometrics, Treatment, Cognitive Processes
Keywords
ketamine, treatment-resistant anxiety, social anxiety disorder, post-traumatic stress disorder, obsessive-compulsive disorder, low-dose ketamine, maintenance therapy, dose-response relationship, treatment response, tolerability, off-label drug use

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Systematic review and meta-analysis of randomized controlled trials of ketamine in the treatment of refractory anxiety spectrum disorders. https://app.cochat.ai/papers/10.1177/20451253211056743
The paper
Whittaker, E., Dadabayev, A. R., Joshi, S. A., & Glue, P. (2021). Systematic review and meta-analysis of randomized controlled trials of ketamine in the treatment of refractory anxiety spectrum disorders. Therapeutic Advances in Psychopharmacology. https://doi.org/10.1177/20451253211056743

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.